Descrizione del progetto
Migliorare la sicurezza dei farmaci
Gli eventi dannosi associati ad alcuni farmaci sono noti come reazioni avverse e possono essere correlati alla dose o al momento della somministrazione, oppure possono scaturire dalla sospensione o dal fallimento della terapia. Il progetto MEDIKURA, finanziato dall’UE, ha sviluppato un’infrastruttura digitale per la raccolta e l’analisi dei dati sulle reazioni avverse al fine di migliorare la sicurezza dei farmaci. La piattaforma basata su cloud è accessibile a pazienti, medici e aziende farmaceutiche come approccio trasparente e centralizzato per la segnalazione delle reazioni avverse. A lungo termine, si prevede che la piattaforma acceleri la scoperta di farmaci basati sui dati e riduca al minimo le reazioni avverse.
Obiettivo
The mission of MEDIKURA is to digitize drug safety: our process innovation helps pharma companies to capture, enrich, and analyze drug-related data provided by patients and doctors. We address the societal problem that more than 200,000 European citizens die from Adverse Drug Reactions (ADRs, colloquially referred to as drug side-effects) every year, whereas less than 1% of ADR cases are officially reported by patients and doctors. To improve drug safety, the new EU regulation ICH E2B(R3) came into effect in late 2017 - as a result, pharma companies are subject to increasing cost and time pressure in ADR monitoring.
Our solution is to build the digital infrastructure for ADR data – to improve drug safety, enable more targeted therapies, and accelerate data-driven drug discovery. We streamline the process of capturing, enriching, and analyzing ADR data through a cloud-based platform that connects pharma companies with patients and doctors. Our goal is to replace the decentralized, analogue drug safety process with a transparent, centralized, and digital system. The resulting value proposition to pharma companies is three-fold. In terms of time savings, we reduce the timespan to close a ADR case and report it to public authorities by more than 50%. In terms of money, we can save processing cost of more than 50% per ADR case and reduce liability risk significantly. In terms of data quality, we provide comprehensive information through a digital backchannel to both patients and doctors that allows to enrich drug-related data and prepare it for subsequent analyses.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencescomputer and information sciencesdata sciencedata exchange
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
80335 MUNCHEN
Germania
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.